• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Community Pharmacy CYP2C19 Testing Provides Preliminary Evidence Supporting Operational Feasibility

by
November 17, 2026
in Health
Reading Time: 3 mins read
0
Community Pharmacy CYP2C19 Testing Provides Preliminary Evidence Supporting Operational Feasibility

Community Pharmacy CYP2C19 Testing Provides Preliminary Evidence Supporting Operational Feasibility

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Pharmacist-led genetic testing models in community pharmacies achieved testing success rates between 98% and 100%, offering preliminary evidence that CYP2C19 testing to guide clopidogrel therapy is operationally feasible in retail healthcare settings.

In a systematic review conducted according to PRISMA guidelines, investigators searched PubMed, ProQuest, Cochrane Central, Scopus, and EBSCO from database inception through December 23, 2025. From an initial pool of 42 screened records, three prospective feasibility studies met the eligibility criteria to evaluate community pharmacy delivery of CYP2C19 testing.

Pharmacogenomic testing aims to improve drug efficacy and safety by tailoring pharmacological regimens to individual genetic profiles. CYP2C19 testing for clopidogrel management represents a key clinical application, especially for cardiovascular patients, with accessible community pharmacies evaluated as potential delivery sites.

The reviewed investigations evaluated multiple outcomes, including clinical, operational, economic, patient-reported, and provider-reported measures. While overall testing success remained high across all assessed pharmacist-led frameworks, only point-of-care testing platforms enabled rapid turnaround times for genetic results.

Patient-reported feedback across the trials was largely favorable, with most participants identifying community pharmacies as appropriate locations for pharmacogenetic testing. Pharmacists likewise reported added clinical value from offering the service, though they highlighted persistent obstacles including workflow integration hurdles, knowledge gaps, and reimbursement difficulties.

Economic findings remained mixed across the included literature. Point-of-care testing demonstrated potential cost savings when rates of genotype-guided therapy modifications were higher, whereas reimbursement restrictions hindered implementation in alternative settings. The review concluded that sustainable implementation will require dedicated funding mechanisms, routine workflow integration, and enhanced provider education.

The systematic review focused on the delivery of pharmacogenetic testing within community pharmacy environments as a practical model for personalizing medication regimens. In cardiovascular care, tailoring drug therapy to individual genetic profiles holds significant promise for improving both drug efficacy and patient safety, with CYP2C19 testing for clopidogrel management representing one of the most clinically relevant applications of this approach. As accessible healthcare settings, community pharmacies may provide a practical model for delivering pharmacogenetic services. By evaluating how genetic screening can be conducted within these accessible retail settings, the review sought to establish whether community-based pharmacists can effectively deliver CYP2C19-guided clopidogrel management.

To establish the current evidence base, the investigators conducted a comprehensive literature search across five major scientific and medical databases, encompassing PubMed, ProQuest, Cochrane Central, Scopus, and EBSCO. In accordance with PRISMA guidelines, the search protocol evaluated literature from database inception through December 23, 2025, specifically screening for studies that assessed CYP2C19 testing performed in community pharmacy locations. The literature search identified 42 studies during initial screening, but following detailed evaluation against the predefined inclusion criteria, only three prospective studies qualified for inclusion in the review. All three prospective studies evaluated pharmacist-led CYP2C19 testing models in community pharmacies.

The prospective studies identified by the review evaluated five distinct categories of outcomes: clinical outcomes, operational measures, economic evaluations, patient-reported perceptions, and provider-reported feedback. Operationally, the pharmacist-led models demonstrated high testing success rates, ranging between 98% and 100% across the evaluated cohorts. Only point-of-care testing technologies enabled rapid turnaround times for genetic test results within the community pharmacy environment.

Patient perceptions were generally favorable, with the majority of surveyed individuals viewing community pharmacies as appropriate and acceptable healthcare locations for undergoing pharmacogenetic testing. Pharmacists participating in the evaluated programs similarly affirmed the added clinical value that genetic testing brought to patient care. Pharmacists cited barriers such as reimbursement challenges, workflow integration, and knowledge gaps.

Economic evaluations across the included prospective studies produced mixed findings regarding cost-effectiveness and financial sustainability. Point-of-care CYP2C19 testing demonstrated potential cost savings, but these economic benefits were observed specifically under conditions characterized by higher rates of genotype-guided therapy modification. Reimbursement limitations hindered implementation in other settings. Consequently, the systematic review concluded that current research provides preliminary evidence supporting the operational feasibility of community pharmacy-based CYP2C19 testing for clopidogrel therapy. To transition from preliminary feasibility to sustainable routine practice, the authors emphasized that future healthcare initiatives must focus on establishing robust funding mechanisms, enhancing formal provider education, and embedding pharmacogenetic protocols directly into standard pharmacy workflows.

Subject of Research: Feasibility of pharmacist-led CYP2C19 genetic testing for clopidogrel management in community pharmacies

Article Title: Feasibility of CYP2C19-guided clopidogrel therapy in community pharmacy: a systematic review

Article References: Mohammed, S., Mohammed, N., Ali, Z., Ghariba, Y., Al-Muftah, W., Abdel-Latif, R., El-Menyar, A., & Sim, M. S. (2026). Feasibility of CYP2C19-guided clopidogrel therapy in community pharmacy: a systematic review. Frontiers in Pharmacology, 17, Article 1871437. https://doi.org/10.3389/fphar.2026.1871437

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1871437

Keywords: CYP2C19, clopidogrel, pharmacogenetics, community pharmacy, pharmacogenomic testing, point-of-care testing, cardiovascular therapy, pharmacist-led testing, feasibility studies, systematic review, turnaround time, patient perceptions, reimbursement barriers, workflow integration, provider education, genotype-guided therapy, PRISMA guidelines

News Source: Ophelia Keating. (November 17, 2026). Community Pharmacy CYP2C19 Testing Provides Preliminary Evidence Supporting Operational Feasibility. Scienmag.

Tags: cardiovascular therapyclopidogrelcommunity pharmacyCYP2C19feasibility studiesgenotype-guided therapypatient perceptionspharmacist-led testingPharmacogeneticspharmacogenomic testingpoint-of-care testingPRISMA guidelinesprovider educationreimbursement barrierssystematic reviewturnaround timeworkflow integration
Share12Tweet7Share2ShareShareShare1

Related Posts

Five Clinical Factors Predict Diabetic Retinopathy Risk in Type 2 Diabetes

Five Clinical Factors Predict Diabetic Retinopathy Risk in Type 2 Diabetes

November 17, 2026
Abdominal CT Radiomics Identifies Prevalent Heart Disease in Type 2 Diabetes

Abdominal CT Radiomics Identifies Prevalent Heart Disease in Type 2 Diabetes

November 17, 2026

Researchers Propose D-Allulose Framework to Test Metabolic Signaling and Aging

November 17, 2026

Gut Microbiome Shifts Linked to Depressive Symptoms in Diabetes Patients

November 17, 2026

POPULAR NEWS

  • Five Clinical Factors Predict Diabetic Retinopathy Risk in Type 2 Diabetes

    Five Clinical Factors Predict Diabetic Retinopathy Risk in Type 2 Diabetes

    29 shares
    Share 12 Tweet 7
  • Abdominal CT Radiomics Identifies Prevalent Heart Disease in Type 2 Diabetes

    29 shares
    Share 12 Tweet 7
  • Researchers Propose D-Allulose Framework to Test Metabolic Signaling and Aging

    29 shares
    Share 12 Tweet 7
  • Gut Microbiome Shifts Linked to Depressive Symptoms in Diabetes Patients

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Five Clinical Factors Predict Diabetic Retinopathy Risk in Type 2 Diabetes

Abdominal CT Radiomics Identifies Prevalent Heart Disease in Type 2 Diabetes

Researchers Propose D-Allulose Framework to Test Metabolic Signaling and Aging

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.